man' have shown that the small intestine synthesises several of the apoproteins which occur in chylomicrons, including apoB48, apoA-IV and apoA-1, and Wu and Windmueller6 have shown that over 50% of the apoA-I and apoA-IV come from the small intestine.
Although intestinal lymph is undoubtedly the major pathway of absorption for cholesterol and the fat soluble vitamins, it is probable that some absorption also occurs via the portal vein. Evidence for this has been put forward for vitamin E by MacMahon et al,4 who found higher concentrations of labelled ca-tocopherol in portal venous than in aortic plasma after oral administration. This presumably explains why small amounts of vitamin E can be demonstrated in the blood of treated patients with a13-lipoproteinaemia, in whom lymphatic transport of lipids cannot occur.
INTRAVASCUt AR METABOLISM
Chylomicrons mix with HDL in lymph, pick up apoE and C, and then get partially degraded by lipoprotein lipase. The resulting chylomicron remnants are quickly taken up by chylomicron remnant receptors in the liver. It is thought that this process is mediated by specific receptors which recognise the apoE on the surface of remnant particles but are metabolically distinct from LDL receptors which recognise apoBl(1) as well as apoE. During lipolysis, some of the free cholesterol and lecithin on the surface of chylomicrons is released into plasma and this coalesces with nascent HDL3 particles which haive been secreted by the liver and the small intestine. As a result of the action of lecithin:cholesterol acyltransferase (LCAT) the free cholesterol gets esterified to cholesterol ester and the particle enlarges and becomes HDL2. Very low density lipoprotein (VLDL) containing apoBI100, is synthesised predominantly in the liver but to some extent in the small intestine. This too gets hydrolysed by the action of lipoprotein lipase to form VLDL remnants. The latter are then either taken up by the LDL receptor or are acted upon by hepatic lipase to give rise to LDL. Low density lipoprotein circulatcs in plisma-alid eventually gets taken up by' LDL receptors locaited both in peripheral cells and in the liver.
Consequences of acquired malabsorption
Malabsorption can be secondary to intraluminal dysfunction, as in pnacreatic insufficiency, inflammatory bowel disease and intestinal resection or it can be associated with mucosal dysfunction, as found in coeliac disease, tropical sprue, and after the administration of large doses of neomycin. It can also be caused by lymphatic dysfunction, as seen in intestinal lymphangiectasia, Whipple's disease and filariasis. Lastly, it can be secondary to manoeuvres which stimulates bile acid excretion, such as the administration of anion-exchange resins or the creation of a partial ileal bypass. FAT of sunlight or dietary deficiency is a more important factor in causing their osteomalacia."' In contrast, patients with adult coeliac disease often show marked malabsorption of vitamin D, the severity being directly proportional to the degree of steatorrhoea.x Studies on the absorption of vitamin E showed marked malabsorption in two patients with intestinal lymphangiectasia. 7 A particularly striking case of osteomalacia, referred to in the Introduction, was associated with megaloblastic anaemia and steatorrhoea secondary to a stricture of the terminal ileum," as illustrated in Figures 1 and 2 . It seems probable that the ileal lesion was responsible not only for malabsorption of vitamin B12 but also of bile acids, thereby impairing micelle formation and causing marked malabsorption of vitamin D, comparable with that demonstrated in rats fed cholestyramine." ESSENTIAL FATTY ACID DEFICIENCY Shimoyama et al'" examined the fatty acid composition of plasma lipids in patients with malabsorption and showed that there was a decrease in the proportion of linoleic acid (18:2) and arachidonic acid (20:4) in malabsorbers compared with healthy controls and patients without malabsorption. These changes were most marked in the fatty acid composition of cholesterol esters and lecithin.
When various categories of malabsorption were examined it was found that the decrease in essential fatty acids was most marked in patients who had an intestinal resection. Subsequently, Press et Figure 3 .
SECONDARY HYPOI IPOPROTEINAEMIA It is well recognised that patients with fat malabsorption often show evidence of hypolipoproteinaemia. This is particularly marked in patients with primary malabsorption, such as abetalipoproteinaemia and familial hypobetalipoproteinaemia, but it also occurs in patients with malabsorption secondary to various underlying causes.
Thompson and Miller'" measured plasma lipids in patients with secondary malabsorption and found that plasma triglyceride concentrations were either normal or raised. In contrast, their plasma cholesterol and phospholipid concentrations were nearly always reduced. Quantification of plasma lipoproteins by ultracentrifugation showed that VLDL concentrations were either normal or raised, but LDL concentrations tended to be reduced, especially in men, whereas in women there was a more marked reduction in HDL, as shown in Figure 4 . Press andi Thompson'h measured plasma postheparin lipolytic activity in some of these patients and showed that the activity of lipoprotein lipase was markedly reduced, which provided an explanation for the increased levels of VLDL and triglyceride.
In addition to noticing that the concentration of LDL was reduced, Thompson and Miller'' showed that its composition was abnormal, in that there was a considerable reduction in the percentage of cholesterol ester in the LDL of malabsorbers and an increase in the percentage of triglyceride, these changes being inversely correlated. Miller and Thompsonv then showed that LCAT activity in the plasma of malabsorbers was reduced and suggested that this was responsible for the decrease in the cholesterol ester content of their LDL. It is now time to consider the other side of the coinnamely, the various ways in which malabsorption can be deliberately induced in order to decrease serum lipids in patients with hyperlipidaemia. One means of doing this is by administering neomycin in a dose of 1-2 g a day. The numerous amino groups on neomycin make it highly cationic and when added in titro to a solution of mixed micelles, which have a net negative charge, precipitation occurs due to ionic interaction. " Neomycin precipitates virtually all the fatty acid, monoglyceride and cholesterol present in mixed micelles but only a small proportion of the taurocholate.
Neomycin was introduced as a cholesterol lowering agent by Samuel who used it to treat patients with heterozygous familial hypercholesterolaemia.
Studies in patients given a test meal followed by aspiration and ultracentrifugation of the duodenal contents showed that most of the cholesterol, bile acid and fatty acid was present in the micellar phase. When neomycin was given at the same time as the test meal, however, there was a very significant increase in the amount of cholesterol and fatty acid in the precipitate.
The functional consequences of this action were assessed by measuring the faecal excretion of fat and cholesterol off and on neomycin. 
